Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)
OTCMKTS
· Delayed Price · Currency is USD
0.1000
-0.0218 (-17.90%)
May 7, 2025, 4:00 PM EDT
SHPHF Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Revenue | 1,901 | 1,861 | 2,181 | 3,038 | 2,464 | Upgrade
|
Revenue Growth (YoY) | 2.18% | -14.70% | -28.21% | 23.30% | -14.39% | Upgrade
|
Cost of Revenue | 659.4 | 564.9 | 693.61 | 607.9 | 549.78 | Upgrade
|
Gross Profit | 1,242 | 1,296 | 1,488 | 2,430 | 1,914 | Upgrade
|
Selling, General & Admin | 1,175 | 911.22 | 1,023 | 1,129 | 858.58 | Upgrade
|
Research & Development | 473.93 | 577.66 | 936.58 | 868.07 | 729.16 | Upgrade
|
Other Operating Expenses | -18.29 | -52.69 | 63.72 | -242.74 | -159.1 | Upgrade
|
Operating Expenses | 1,631 | 1,436 | 2,024 | 1,754 | 1,429 | Upgrade
|
Operating Income | -389.41 | -140.54 | -536.05 | 676.2 | 485.82 | Upgrade
|
Interest Expense | -274.93 | -269.34 | -211.18 | -117.35 | -8.22 | Upgrade
|
Interest & Investment Income | 175.55 | 147.91 | 146.79 | 163.95 | 135.73 | Upgrade
|
Earnings From Equity Investments | -15.23 | -53.62 | -80.88 | -158.58 | -13.06 | Upgrade
|
Currency Exchange Gain (Loss) | 11.64 | -6.76 | -18.39 | -4.57 | 7.27 | Upgrade
|
EBT Excluding Unusual Items | -492.38 | -322.35 | -699.7 | 559.64 | 607.54 | Upgrade
|
Impairment of Goodwill | - | - | -8.76 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | 51.49 | 153.02 | -279.36 | 8.44 | 83.17 | Upgrade
|
Gain (Loss) on Sale of Assets | 12.6 | 8.07 | 194.09 | 59.23 | 72.31 | Upgrade
|
Asset Writedown | - | - | -1,329 | -131.3 | - | Upgrade
|
Other Unusual Items | - | - | - | - | 2.83 | Upgrade
|
Pretax Income | -428.29 | -161.26 | -2,123 | 496.01 | 765.84 | Upgrade
|
Income Tax Expense | 43.26 | 96.43 | 196.79 | 253.12 | 219.04 | Upgrade
|
Earnings From Continuing Operations | -471.55 | -257.69 | -2,320 | 242.89 | 546.8 | Upgrade
|
Earnings From Discontinued Operations | - | - | 36.3 | -10.12 | -34.92 | Upgrade
|
Net Income to Company | -471.55 | -257.69 | -2,283 | 232.77 | 511.89 | Upgrade
|
Minority Interest in Earnings | 254.89 | 203.67 | 368.36 | 183.74 | -38.51 | Upgrade
|
Net Income | -216.66 | -54.02 | -1,915 | 416.51 | 473.38 | Upgrade
|
Net Income to Common | -216.66 | -54.02 | -1,915 | 416.51 | 473.38 | Upgrade
|
Net Income Growth | - | - | - | -12.01% | - | Upgrade
|
Shares Outstanding (Basic) | 9,266 | 9,297 | 9,330 | 9,431 | 9,466 | Upgrade
|
Shares Outstanding (Diluted) | 9,266 | 9,297 | 9,330 | 9,483 | 9,466 | Upgrade
|
Shares Change (YoY) | -0.33% | -0.35% | -1.62% | 0.19% | -0.03% | Upgrade
|
EPS (Basic) | -0.02 | -0.01 | -0.21 | 0.04 | 0.05 | Upgrade
|
EPS (Diluted) | -0.02 | -0.01 | -0.21 | 0.04 | 0.05 | Upgrade
|
EPS Growth | - | - | - | -12.20% | - | Upgrade
|
Free Cash Flow | - | 74.14 | -355.97 | 64.28 | -279.51 | Upgrade
|
Free Cash Flow Per Share | - | 0.01 | -0.04 | 0.01 | -0.03 | Upgrade
|
Dividend Per Share | 0.019 | - | 0.033 | 0.013 | 0.014 | Upgrade
|
Dividend Growth | - | - | 153.85% | -7.14% | -17.65% | Upgrade
|
Gross Margin | 65.31% | 69.64% | 68.20% | 79.99% | 77.69% | Upgrade
|
Operating Margin | -20.48% | -7.55% | -24.58% | 22.25% | 19.71% | Upgrade
|
Profit Margin | -11.40% | -2.90% | -87.79% | 13.71% | 19.21% | Upgrade
|
Free Cash Flow Margin | - | 3.98% | -16.32% | 2.11% | -11.34% | Upgrade
|
EBITDA | -208.66 | 40.21 | -229.26 | 931.69 | 714.06 | Upgrade
|
EBITDA Margin | -10.97% | 2.16% | -10.51% | 30.66% | 28.98% | Upgrade
|
D&A For EBITDA | 180.75 | 180.75 | 306.79 | 255.49 | 228.25 | Upgrade
|
EBIT | -389.41 | -140.54 | -536.05 | 676.2 | 485.82 | Upgrade
|
EBIT Margin | -20.48% | -7.55% | -24.58% | 22.25% | 19.71% | Upgrade
|
Effective Tax Rate | - | - | - | 51.03% | 28.60% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.